Alkermes settles Lybalvi patent suit with Teva, licenses generic entry for 2039
Alkermes and Teva resolved ANDA litigation over Lybalvi, with Teva's generic allowed to launch starting November 12, 2039, subject to antitrust review.
SEC filing (2)
4 stories
Alkermes and Teva resolved ANDA litigation over Lybalvi, with Teva's generic allowed to launch starting November 12, 2039, subject to antitrust review.
SEC filing (2)
The company highlighted ADHD proof-of-concept data and a new phase 2 depression trial for its orexin 2 receptor agonists alongside quarterly earnings.
SEC filing
Alkermes said the orexin 2 receptor agonist showed dose-dependent symptom improvements in adults with ADHD, with a Phase 2 trial now enrolling and data expected in 2027.
SEC filing
The company confirmed the September 14 board appointment in a September 16 statement that included executive comments and details on Whitaker's background.
SEC filing